InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) saw a significant increase in short interest in August. As of August 31st, there was short interest totaling 215,000 shares, an increase of 73.4% from the August 15th total of 124,000 shares. Based on an average trading volume of 0 shares, the short-interest ratio is currently ? days.
InnoCare Pharma Price Performance
INCPF opened at $1.55 on Friday. InnoCare Pharma has a 12 month low of $1.55 and a 12 month high of $2.31. The company has a 50 day moving average of $1.55 and a 200 day moving average of $1.55.
Analysts Set New Price Targets
Separately, Morgan Stanley upgraded InnoCare Pharma to an “overweight” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.
About InnoCare Pharma
InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.
The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.
Featured Stories
- Five stocks we like better than InnoCare Pharma
- 3 Zero-Fee ETFs Worth More Than Their Cost
- 3 Nimble Free Cash Flow Names With Light Assets
- Intel’s Ohio Lifeline? Why the SK Hynix Talks Matter
- Generac Plugs into Amazon for an $8B AI-Powered Deal
Receive News & Ratings for InnoCare Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InnoCare Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
